A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

New research shows some gut bacteria mimic myelin, tricking immunity to attack nerves and worsen MS. Non-inflammatory ...

Elsa Mendoza navigates life with multiple sclerosis, using a wheelchair while her son, Fernando, excels as a quarterback ...

A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Tolebrutinib received provisional approval in the United Arab Emirates in July 2025 for non-relapsing secondary progressive ...

Dec 15 () - Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to ​a U. regulatory ...

Here's what to know on Indiana football and Heisman Trophy winner Fernando Mendoza's mom and her battle with MS.

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.